AbbVie Cash on Hand 2012-2026 | ABBV | MacroTrends

AbbVie Cash on Hand 2012-2026 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for the quarter ending March 31, 2026 was $5.671B, a 22.16% decline year-over-year.

AbbVie cash on hand for 2024 was $5.555B, a 56.66% decline from 2023.
AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.

AbbVie Cash on Hand 2012-2026 | ABBV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbbVie cash on hand for 2024 was $5.555B, a 56.66% decline from 2023.
AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.

Related Stocks
Company Name	Market Cap
Eli Lilly (LLY)	$887.6B
Johnson & Johnson (JNJ)	$574.4B
Roche Holding AG (RHHBY)	$318.8B
Merck (MRK)	$299.9B
Novartis AG (NVS)	$294B
Novo Nordisk (NVO)	$167.5B
Pfizer (PFE)	$153.1B
Sanofi (SNY)	$114B
Bayer (BAYRY)	$46.2B
Innoviva (INVA)	$1.8B